Teva Secures $400 Million from Blackstone to Advance TL1A-Targeting Antibody for IBD Treatment
Key Insights
Teva Pharmaceutical and Blackstone Life Sciences (search) announced a $400 million strategic funding agreement to support the development of duvakitug, a human monoclonal antibody targeting TL1A (search) for inflammatory bowel disease (search) treatment.
Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (search) and Crohn's disease (search), with recent phase 2b maintenance data demonstrating clinically meaningful durable efficacy in both conditions.
The four-year funding arrangement supports Teva's Pivot to Growth strategy while providing Blackstone with regulatory and commercial milestones plus low single-digit royalties on worldwide sales.
Teva Pharmaceutical Industries (search) and Blackstone Life Sciences (search) announced a $400 million strategic funding agreement to advance duvakitug, a human monoclonal antibody targeting TL1A (search) for the treatment of inflammatory bowel disease (search) (IBD (search)). The four-year funding arrangement will support continued clinical development of the phase 3 candidate for ulcerative colitis (search) (UC) and Crohn's disease (search) (CD).
Strategic Partnership Details
Under the agreement announced March 3, 2026, Blackstone Life Sciences (search) will provide $400 million spread across four years to fund ongoing and future development costs for duvakitug. In return, BXLS will be eligible for regulatory and commercial milestones as well as low single-digit royalties on duvakitug worldwide sales, subject to customary terms and conditions.
"Today's announcement highlights how we are turning strategy into action under Pivot to Growth," said Evan Lippman, Executive Vice President, Business Development, Teva. "By pursuing disciplined, capital-efficient partnerships, we are accelerating pipeline advancement while maintaining financial strength."
The funding supports Teva's broader Pivot to Growth strategy aimed at accelerating its innovative pipeline and driving long-term growth. As part of the funding arrangement, Teva will pay BXLS a milestone payment subject to FDA approval of duvakitug.
TL1A Target and Mechanism of Action
Duvakitug represents a human monoclonal antibody targeting TL1A (search), described as a promising target with potential for broad therapeutic application across multiple indications. TL1A signaling is believed to amplify inflammation and drive fibrosis associated with IBD (search) through binding to its receptor, DR3 (search).
The antibody preferentially inhibits TL1A (search)-DR3 (search) signaling over DcR3 (decoy receptor 3) binding, with the potential to reduce inflammation and fibrosis. Both companies recently announced phase 2b duvakitug maintenance data demonstrating clinically meaningful durable efficacy in UC and CD.
Clinical Development and Partnership Structure
Duvakitug is currently in phase 3 clinical studies for the treatment of UC and CD. Under a separate agreement announced in 2023, Teva is co-developing and, subject to regulatory approval, will be co-commercializing this asset with Sanofi.
"Duvakitug has the potential to be a best-in-class therapy in a large and growing space, and the Teva and Sanofi teams are well positioned to develop and commercialize this important medicine," said Paris Panayiotopoulos, Senior Managing Director, BXLS.
The safety and efficacy of duvakitug have not been reviewed by any regulatory authority.
Addressing Unmet Medical Need
IBD (search) represents an autoimmune disorder characterized by chronic inflammation of the gastrointestinal tract. Globally, approximately 4.9 million cases of IBD have been identified, with incidence rising in several regions. The two main types of IBD are UC and CD, characterized by repetitive cycles of relapses and remission.
Common symptoms of both conditions include persistent diarrhea, rectal bleeding, abdominal pain, loss of appetite, and weight loss. Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication characterized by excessive accumulation of scar tissue in the intestinal wall, which may cause narrowing and obstruction.
Currently, there is no cure for IBD (search), with treatment goals focused on inducing and maintaining remission and preventing flares.
Investment Platform Perspective
"We are excited to partner with Teva and support their innovation priorities as they advance a critical new product to patients who have significant unmet need," said Dr. Nicholas Galakatos, Global Head of BXLS. "This transaction further demonstrates our focus on partnering with leading biopharmaceutical companies to execute their growth initiatives."
Blackstone Life Sciences (search) operates as a leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. The platform currently has $15 billion in assets under management and combines scale investments with hands-on operational leadership to bring promising new medicines and medical technologies to market.